Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
Venkateshwar Rao Gummadi, Bangalore (IN); and Susanta Samajdar, Bangalore (IN)
Assigned to Aurigene Oncology Limited, Bangalore (IN)
Filed by Aurigene Oncology Limited, Bangalore (IN)
Filed on Apr. 28, 2023, as Appl. No. 18/141,008.
Application 18/141,008 is a continuation of application No. 17/245,611, filed on Apr. 30, 2021, granted, now 11,691,987.
Application 17/245,611 is a continuation of application No. 16/795,394, filed on Feb. 19, 2020, granted, now 10,995,100.
Application 16/795,394 is a continuation of application No. 16/054,512, filed on Aug. 3, 2018, granted, now 10,640,517.
Application 16/054,512 is a continuation of application No. 15/667,173, filed on Aug. 2, 2017, granted, now 10,047,104.
Application 15/667,173 is a continuation of application No. 15/111,000, granted, now 9,732,095, previously published as PCT/IB2015/050217, filed on Jan. 12, 2015.
Claims priority of application No. 158/CHE/2014 (IN), filed on Jan. 13, 2014; and application No. 3000/CHE/2014 (IN), filed on Jun. 20, 2014.
Prior Publication US 2023/0331740 A1, Oct. 19, 2023
